SAGE-718 ( DrugBank: Sage )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病2
8ハンチントン病4

6. パーキンソン病


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05318937
(ClinicalTrials.gov)
July 6, 20221/4/2022A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive ImpairmentA Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Parkinson's Disease Cognitive ImpairmentParkinson Disease;Cognitive DysfunctionDrug: SAGE-718;Drug: SAGE-718-matching placeboSage TherapeuticsNULLRecruiting50 Years75 YearsAll76Phase 2United States
2NCT04476017
(ClinicalTrials.gov)
September 11, 202015/7/2020A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive ImpairmentParkinson Disease;Cognitive DysfunctionDrug: SAGE-718Sage TherapeuticsNULLCompleted50 Years75 YearsAll18Phase 2United States

8. ハンチントン病


臨床試験数 : 242 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05655520
(ClinicalTrials.gov)
December 14, 20229/12/2022A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's DiseaseA Phase 3, Multicenter, Open-label Safety Study to Evaluate the Long-term Safety and Tolerability of SAGE-718 in Participants With Huntington's DiseaseHuntington DiseaseDrug: SAGE-718Sage TherapeuticsNULLRecruiting25 Years65 YearsAll300Phase 3United States
2NCT05358821
(ClinicalTrials.gov)
June 22, 202227/4/2022A Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants With Huntington's DiseaseA 28-Day Randomized, Placebo-Controlled, Double-Blind, Parallel Groups and Normative Comparison Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants With Huntington's DiseaseHuntington DiseaseDrug: SAGE-718;Drug: PlaceboSage TherapeuticsNULLRecruiting25 Years65 YearsAll80Phase 2United States
3NCT05107128
(ClinicalTrials.gov)
February 10, 202225/10/2021A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's DiseaseHuntington's DiseaseDrug: SAGE-718;Drug: PlaceboSage TherapeuticsNULLRecruiting25 Years65 YearsAll178Phase 2United States;Australia;Canada;United Kingdom
4NCT03787758
(ClinicalTrials.gov)
February 28, 201917/12/2018A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part BA Phase 1, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Healthy Adults With an Open-label Cohort of Patients With Huntington's DiseaseHuntington DiseaseDrug: SAGE-718Sage TherapeuticsNULLCompleted18 Years70 YearsAll6Phase 1United States